Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)
Authors:
Open Access
- 23 May 2024
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 27 (8) , 1046-1057
Abstract
No abstract availableKeywords
Funding Information
- Zorginstituut Nederland
This publication has 36 references indexed in Scilit:
- Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlookDrug Discovery Today, 2022
- Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future OptionsApplied Health Economics and Health Policy, 2022
- Precision Reimbursement for Precision Medicine: Using Real‐World Evidence to Evolve From Trial‐and‐Project to Track‐and‐Pay to Learn‐and‐PredictClinical Pharmacology & Therapeutics, 2021
- The Challenges of Outcomes-Based Contract Implementation for Medicines in EuropePharmacoEconomics, 2021
- Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and TisagenlecleucelPharmacoEconomics, 2021
- Integrative Review of Managed Entry Agreements: Chances and LimitationsPharmacoEconomics, 2020
- The impact of managed entry agreements on pharmaceutical pricesHealth Economics, 2020
- The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical AssessmentsPharmacoEconomics, 2019
- Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcareThe European Journal of Health Economics, 2018
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010